TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1983349
Drug: Intravenous pentagastrin
Normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentagastrin (0.6 microgram.kg/h) with ranitidine 300 mg
Study: 530855
Drug: One-step treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step treatment
Study: 530855
Drug: Planned interval
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Planned interval treatment
Study: 24368466
Drug: Diflunisal, 250
Normalized name: Diflunisal, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal, 250 mg twice daily for 2 years
Study: 24368466
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 2 years
Study: 21807773
Drug: Intravenous slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous slow 5 IU oxytocin bolus over 1 minute and additional 40 IU oxytocin infusion in 500 mL of 0.9% saline solution over 4 hours (bolus and infusion)
Study: 21807773
Drug: 5 IU
Normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU oxytocin bolus over 1 minute and 500 mL of 0.9% saline solution over 4 hours (placebo infusion) (bolus only)
Study: 19102515
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 or 40 mg/day
Study: 19102515
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 or 40 mg/day with or without hydrochlorothiazide
Study: 16883966
Drug: Riboflavin supplementation
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin supplementation (0.625 mg/day)
Study: 16883966
Drug: B vitamin
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamin compound supplementation (riboflavin 0.625 mg/day, thiamin 0.512 mg/day, nicotinic acid 0.365 mg/day, folic acid 0.13 mg/day)
Study: 9469527
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release morphine
Study: 8184813
Drug: Lisinopril 5
Normalized name: lisinopril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5 mg (target 20 mg)/day (n = 20)
Study: 3309233
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (30 to 40 mg/kg/24 hr)
Study: 31964660
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy with standard podiatry care over 24 weeks
Study: 29535130
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus 9 weeks of trastuzumab
Study: 29535130
Drug: Combined analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined analysis of both treatment arms
Study: 24157957
Drug: Aleglitazar plus
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar plus single-dose warfarin
Study: 20418072
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg/day for 3 weeks
Study: 18714059
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg) plus vitamin B(12) (0.4 mg)
Study: 12507972
Drug: Vitamin B(6)
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B(6) (40 mg)
Study: 10339732
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - Beclomethasone dipropionate (BDP) 0.4 mg/day
Study: 2117204
Drug: Curosurf (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curosurf (200 mg/kg)
Study: 323793
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza A vaccine administered intranasally
Study: 323793
Drug: Killed subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed subunit vaccine
Study: 323793
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza A vaccine
Study: 323793
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza A vaccine and Killed subunit vaccine
Study: 31625653
Drug: Adapted antibiotic
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted antibiotic stewardship intervention
Study: 30879569
Drug: Marine n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine n-3 PUFAs (2.6 g daily)
Study: 24840781
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate 6 g/day
Study: 24840781
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate 4 g/day
Study: 24800383
Drug: Email-linked website
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Email-linked website intervention with ten consecutive weekly emails and two motivational phone calls
Study: 17019594
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg/day for 2 weeks)
Study: 10211008
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 21, 12 and 6 mg kg‐1 h‐1 for a minimum of 2 hours
Study: 10150182
Drug: Defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (400 mg b.i.d., oral)
Study: 3127417
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified FSH (225 IU daily for 10 days)
Study: 3127417
Drug: Human menopausal
Normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human menopausal gonadotropin (hMG; 225 IU daily for 10 days)
Study: 30277639
Drug: ABVE-PC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVE-PC chemotherapy followed by response evaluation
Study: 30277639
Drug: Involved field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field radiotherapy (IFRT) or no further therapy for RERs with CR
Study: 28855976
Drug: Hydroxytyrosol (HT)
DrugBank: Hydroxytyrosol (DB12771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxytyrosol (HT) 15 mg/day for 3 weeks
Study: 26547357
Drug: Vericiguat 10
Normalized name: vericiguat 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 10 mg
Study: 26547357
Drug: Pooled vericiguat
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pooled vericiguat groups (1.25 mg, 2.5 mg, 5 mg, 10 mg)
Study: 26547357
Drug: Vericiguat (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat (various doses)
Study: 23568622
Drug: 1-carbamimidoyl-L-proline (CLP)
Normalized name: CYPERUS PROLIFER WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-carbamimidoyl-L-proline (CLP)
Study: 19062477
Drug: Manix 600
Normalized name: witch hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manix 600 mg for 13 weeks
Study: 9386082
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) - 10 mg infused in 500 mL of normal saline
Study: 9386082
Drug: Aprotinin (AP)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (AP) - High-dose: 280 mg loading dose, 280 mg in CPB prime solution, 70 mg/h for 6 hours
Study: 3203055
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg rectally as premedication
Study: 30666023
Drug: Home-based follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based follow-up care (HBFC) intervention administered for 12 months
Study: 28926762
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (200mg twice daily)
Study: 24498826
Drug: Isotretinoin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (0.5 mg/kg/day) + Vitamin E (800 IU/day)
Study: 24498826
Drug: Isotretinoin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (0.5 mg/kg/day) + Cod liver oil (800 IU/day)
Study: 22028471
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents or bare metal stents
Study: 19252250
Drug: Disease modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease modifying anti-rheumatic drugs (DMARDs), specifically methotrexate (MTX) as the anchor drug.
Study: 19252250
Drug: Disease modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease modifying anti-rheumatic drugs (DMARDs)
Study: 9602764
Drug: ibuprofen for
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen for 3 weeks
Study: 9602764
Drug: ibuprofen for
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen for 1 week and placebo for the next 2 weeks
Study: 8042206
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg GM-1 followed by 100 mg GM-1 daily for 10 days and 100 mg GM-1 intramuscularly for 11-21 days
Study: 3281620
Drug: Diuretic-metoprolol combination
Normalized name: metoprolol and other diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic-metoprolol combination therapy
Study: 3281620
Drug: High-dose diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose diuretic therapy (100 to 150 mg/d of hydrochlorothiazide)
Study: 29084488
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for depression
Study: 28746222
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg in 5 mL normal saline (NS)
Study: 18582177
Drug: Risperidone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5 to 3.5 mg/day)
Study: 10831925
Drug: Matrix transdermal
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix transdermal 17beta‐estradiol patch
Study: 8991327
Drug: Victimization experiences
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Victimization experiences (e.g., sexual abuse, parental assault, kidnapping)
Study: 6202963
Drug: Felodipine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 12.5 mg t.i.d. for 3 days
Study: 6202963
Drug: Felodipine 25
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 25 mg t.i.d. for 3 days
Study: 6202963
Drug: Felodipine 50
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 50 mg t.i.d. for 3 days
Study: 18317718
Drug: BCG-RIVM 2x10^8
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-RIVM 2x10^8 CFU in six weekly instillations
Study: 18317718
Drug: MMC 20
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC 20 mg in six weekly instillations
Study: 18317718
Drug: MMC 20
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC 20 mg in six weekly instillations with subsequent monthly instillations for 3 years
Study: 18317718
Drug: MMC 20
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC 20 mg instilled weekly six times
Study: 12808486
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg daily) added after 12 weeks
Study: 8897119
Drug: Dexamethasone (DEX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (DEX), 0.5 mg at night
Study: 1740677
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy (CHT)
Study: 31520525
Drug: Triheptanoin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triheptanoin (1 g/kg/day)
Study: 30064968
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group who tried the intervention
Study: 25755685
Drug: 9.5 mg/24
Normalized name: Exelon, 9.5 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.5 mg/24 h rivastigmine patch
Study: 18041917
Drug: Higher total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher total doses of radiation (1.8-2 Gy)
Study: 18041917
Drug: Hypofractionated regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated regimens (larger daily doses)
Study: 18041917
Drug: Conventional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional daily doses (1.8-2 Gy)
Study: 8607589
Drug: Warfarin (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted dose, INR 2.0 to 3.0)
Study: 2990711
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor (TF) immunotherapy for 18 months in addition to radiotherapy
Study: 30328496
Drug: Posterior-Stabilized (PS)
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior-Stabilized (PS) implants
Study: 30328496
Drug: Medially Congruent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medially Congruent (MC) implants
Study: 22173281
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (37.5 mg/day for 4 days, then 75 mg/day for 6 days)
Study: 22173281
Drug: Desvenlafaxine XR
Normalized name: desvenlafaxine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine XR (50 mg/day for 10 days)
Study: 22173281
Drug: Indinavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (800 mg) co-administered on day 12
Study: 10190404
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with metoprolol + felodipine
Study: 10190404
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with enalaril + hydrochlorothiazide
Study: 2367393
Drug: Ofloxacin 2
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 2 X 200 mg orally for 10 days
Study: 2367393
Drug: Established antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established antibiotics
Study: 28232290
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement and cognitive behavioral therapy intervention (MET/CBT-7)
Study: 15174325
Drug: Mexicor (6-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for unstable angina (UA)
Study: 15174325
Drug: Mexicor (6-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for acute myocardial infarction (MI)
Study: 15174325
Drug: Mexicor (6-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for hypertensive crises (HC)
Study: 15174325
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone for unstable angina (UA)
Study: 15174325
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone for acute myocardial infarction (MI)
Study: 15174325
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone for hypertensive crises (HC)
Study: 11697832
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) 1000 mg/m2, days 1, 8 and 15
Study: 11697832
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2, day 1) plus Vindesine (3 mg/m2, days 1 and 15) (PV)
Study: 20845288
Drug: Intramuscular tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tramadol 100 mg
Study: 7517825
Drug: Intramuscular tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tramadol 300 mg
Study: 31901710
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (50,000 IU weekly for 8 weeks)
Study: 28382551
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg vitamin C + 235 mg vitamin E daily (AO)
Study: 25719419
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone associated with hyaluronic acid (group 3)
Study: 25719419
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone (group 2)
Study: 18986534
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg licofelone twice daily
Study: 6373158
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen twice daily
Study: 17034279
Drug: Guideline standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline standard therapy
Study: 12514268
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of psyllium per day for 30 days
Study: 12514268
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of psyllium per day for 30 days (control)
Study: 10882617
Drug: PRO 542
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRO 542 (0.2-10 mg/kg)
Study: 8891083
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg for the first week, 40 mg for the remaining period)
Study: 1799283
Drug: Fructose alone
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose alone (50 g)
Study: 1799283
Drug: Glucose alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose alone (50 g)
Study: 1799283
Drug: Fructose plus
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose plus starch (50 g fructose + 15 g starch)
Study: 23059357
Drug: Single 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 0.5 mL dose of virosomal subunit influenza vaccine (Inflexal V)
Study: 23059357
Drug: Standard two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard two 0.25 mL doses given four weeks apart
Study: 20147716
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (10 mg/kg body weight, single infusion)
Study: 20147716
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate (1 mg/kg, 15 infusions every other day during a 29-day hospitalization)
Study: 17980416
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg budesonide + 9 microg formoterol (twice daily, 100 microg per dose; n = 20)
Study: 17980416
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg budesonide + 5 or 10 mg montelukast (once daily at bedtime; n = 20)
Study: 17980416
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 10 mg montelukast (n = 20)
Study: 16751933
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg/day)
Study: 16751933
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UH) (5,000 IU t.i.d.)
Study: 14521593
Drug: Ximelagatran 24
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 24 mg bid
Study: 14521593
Drug: Enoxaparin 30
Normalized name: ENOXAPARIN 30MG/0.3ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 30 mg bid
Study: 10413638
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy including bedrest, anti-ischaemic medications, aspirin, and heparin.
Study: 8673551
Drug: Interest in
Normalized name: CATH,INTERMIT,14FR MENTOR #3814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interest in participating in HIV preventive vaccine trials
Study: 8673551
Drug: Perceived peer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived peer willingness to enroll in vaccine trials
Study: 8673551
Drug: Optimism about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimism about success in vaccine development
Study: 8673551
Drug: Vaccine‐induced seroconversion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine‐induced seroconversion
Study: 1765571
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 or 0.50 mg)
Study: 28884296
Drug: Bisphosphonate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate therapy (pamidronate and zoledronic acid, mean 2.95 infusions per patient)
Study: 21178077
Drug: Cereal L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal L fortified with electrolytic iron (54.5 mg iron/100 g cereal)
Study: 21178077
Drug: Cereal M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal M fortified with ferrous fumarate (52.2 mg Fe/100 g)